Table 2.

Responses and Subsequent Consolidation

Response N (%)	Frontline (N=9)	MRD-positive consolidation (N=4)	Relapsed/refractory (N=8)
CR/CRi rate #	9 (100)	-----	5 (63)
MRD negativity by flow *
After cycle 1	9 (100)	3/3 (100)	5/5 (100)
At any time	9 (100)	3/3 (100)	5/5 (100)
MRD negativity by NGS
After cycle 1	4/6 (67)	2 (50)	----
At any time	7/7 (100)	3 (75)
CAR T-cell consolidation	0	1 (25)	0
AlloSCT consolidation	0	2 (50)	5 (63)

Abbreviations: MRD, measurable residual disease; Ph, Philadelphia chromosome; ALL, acute lymphoblastic leukemia; INO, inotuzumab ozogamicin; AlloSCT, allogeneic hematopoietic stem cell transplant; CAR, chimeric antigen receptor; CR, complete remission; CRi, complete remission with incomplete count recovery

^#Including only patients with baseline morphological marrow or extramedullary disease

^*Including only responding patients with baseline flow-detectable marrow disease